NCT05518045View on ClinicalTrials.gov

Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

392

Participants

Timeline

Start Date

August 26, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

LM-108

Administered intravenously

DRUG

Toripalimab

Administered intravenously

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

LaNova Medicines Limited

INDUSTRY